Hum. Reprod. Advance Access published online on January 18, 2007
Human Reproduction, doi:10.1093/humrep/del505
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2007. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
High-dose atorvastatin causes regression of endometriotic implants: a rat model
1 Department of Obstetrics and Gynecology 2 Department of Pathology, Baskent University Faculty of Medicine, Ankara, Turkey 3 Biochemistry Laboratories, Baskent University Hospital, Ankara, Turkey
4 To whom correspondence should be addressed at: Onur Sokak 38/9, 06570 Maltepe Ankara, Turkey. Tel: +90 312 2324400; Fax: +90 312 2323912; E-mail: mesutoktem{at}hotmail.com
BACKGROUND: This prospective randomized-controlled animal study was designed to determine the effects of atorvastatin on experimentally induced endometriosis in a rat model.
METHODS: Thirty-seven Wistar-Albino rats in which endometriotic implants were induced were randomly divided into four groups. Group I (Low-dose atorvastatin group, eight rats) were given 0.5 mg kg–1 day–1 oral atorvastatin. Group II (High-dose atorvastatin group, 10 rats) were given 2.5 mg kg–1 day–1 oral atorvastatin. Group III were given a single dose of 1 mg kg–1 s.c. leuprolide acetate (GnRH agonist group, nine rats). Group IV were given no medication and served as controls (10 rats). All rats received the treatment for 21 days and were then euthanized to assess the implants' size, vascular endothelial growth factor (VEGF) level in peritoneal fluid and histological score.
RESULTS: At the end of the treatment, the mean areas of implants were smaller and VEGF levels in peritoneal fluid were lower in Groups II and III than those in Group I and the control group (all P < 0.05). The mean areas of implants decreased from 41.2 ± 13.9 to 22.7 ± 13.9 mm2 after medication in Group II and decreased from 41.2 ± 18.1 to 13.1 ± 13.8 mm2 in Group III (both P < 0.05), whereas in Group I, the mean area increased from 43.0 ± 12.7 to 50.5 ± 13.9 mm2 (P < 0.05).
CONCLUSIONS: High-dose atorvastatin caused a significant regression of endometriotic implants.
Key words: atorvastatin/angiogenesis/endometriosis/statins/vascular endothelial growth factor
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. L. Bruner-Tran, K. G. Osteen, and A. J. Duleba Simvastatin Protects against the Development of Endometriosis in a Nude Mouse Model J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2489 - 2494. [Abstract] [Full Text] [PDF]
|
|